AUPH vs. PTCT, ADMA, ZLAB, RNA, OGN, ACLX, SWTX, RARE, AKRO, and ALVO
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include PTC Therapeutics (PTCT), ADMA Biologics (ADMA), Zai Lab (ZLAB), Avidity Biosciences (RNA), Organon & Co. (OGN), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs.
PTC Therapeutics (NASDAQ:PTCT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
In the previous week, PTC Therapeutics had 8 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 10 mentions for PTC Therapeutics and 2 mentions for Aurinia Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 1.62 beat PTC Therapeutics' score of 1.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Aurinia Pharmaceuticals has lower revenue, but higher earnings than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Aurinia Pharmaceuticals has a net margin of -10.23% compared to PTC Therapeutics' net margin of -50.32%. PTC Therapeutics' return on equity of 0.00% beat Aurinia Pharmaceuticals' return on equity.
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
PTC Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
PTC Therapeutics presently has a consensus price target of $64.00, suggesting a potential upside of 16.38%. Aurinia Pharmaceuticals has a consensus price target of $11.50, suggesting a potential upside of 35.93%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than PTC Therapeutics.
Aurinia Pharmaceuticals received 9 more outperform votes than PTC Therapeutics when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 61.87% of users gave PTC Therapeutics an outperform vote.
Summary
Aurinia Pharmaceuticals beats PTC Therapeutics on 11 of the 19 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 3/28/2025 by MarketBeat.com Staff
